XML 37 R26.htm IDEA: XBRL DOCUMENT

Subsequent Events	3 Months Ended
Subsequent Events	Mar. 31, 2026
Subsequent Events [Abstract]
Subsequent Events	17. Subsequent Events The Company has evaluated events and transactions occurring subsequent to March 31, 2026 through the date at which the financial statements were issued. On April 2, 2026, the Company sold the rights to certain legacy GlycoMimetics intellectual property assets to PPI-Uproleselan, Inc. for upfront consideration of $1.8 million, with additional potential consideration for future development milestones and sales milestones.